A comprehensive approach to support people and parents living with eczema
While eczema is one of the most common skin conditions, it remains one of the most challenging to live with. Eczema is a chronic (long lasting) condition without a cure. It’s also unique for each person — including symptoms, severity and which treatments may help. Thus, managing eczema can be complex journey based off individual needs. Finding effective treatments can be hard. Finding trusted information can be hard. Chances to engage in research or let your voice be heard can be few.
At OHSU we've launched an initiative with the goal of eliminating some of these challenges that can come from living with eczema. The CLEAR Eczema Center is collection of efforts designed to better support the eczema community in clinical care, lifestyle, education, advocacy and research. We're looking to build upon a legacy of researching and treating eczema at OHSU, with a more comprehensive and easily accessible group of resources available to those with eczema. We hope you can join us as we continue to build these resources, joining with a common goal of reducing the effects eczema has on individuals worldwide.
Sept. 2021: FDA approves topical ruxolitinib for atopic dermatitis, first JAK inhibitor for this indication in the U.S.
The first topical JAK inhibitor approved for AD for mild to moderate atopic dermatitis ages 12 years and older– and the first JAK inhibitor approved for this indication – in the United States.
"What is Eczema?" educational video
Watch the first of our upcoming series of animated eczema educational videos.